ArticleEuropean journal of applied physiology2026
The effect of 14 days Actovegin administration with or without high intensity training on exercise capacity and skeletal muscle mitochondrial respiration.
Article in European journal of applied physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protective role of Actovegin against Cisplatin-evoked testicular damage: evidence from a rat model.Journal of molecular histology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEvidence exists that Actovegin has enhancing effects on mitochondrial respiratory capacity (MRC) in skeletal muscle, and it is well known that high intensity training (HIT) improves MRC and exercise performance. The aim was to investigate the effects of Actovegin administration on exercise performance and mitochondrial respiratory capacity in mice skeletal muscle fibers alone or in combination with HIT.
methods40 healthy male mice were randomized into 4 groups; control (C), Actovegin (A), trained control (CT) and trained Actovegin (AT). All mice were given intraperitoneal injections every other day for 14 days of either 0.1 ml Actovegin (10 mg/ml) or 0.1 ml saline. The training consisted of a HIT protocol (5x1 min at 80-90 % of maximal running speed with 2 minutes of active recovery in between) performed every other day by the trained groups. All mice completed a maximal exercise capacity test before and after the intervention. High-resolution respirometry was used to measure skeletal muscle mitochondrial respiratory capacity. Citrate synthase activity was used as a biomarker for mitochondrial content.
resultsThe CT and AT groups improved their exercise capacity significantly after the 14-day intervention compared to C and A. The increase in performance was significantly higher in the AT group compared to the CT group. Complex I + II linked mitochondrial respiratory capacity was increased in the A, CT and AT groups compared to the C group.
conclusionThis is the first study showing enhancing effects of Actovegin on exercise performance and skeletal muscle mitochondrial respiratory capacity with in vivo administration in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.